Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials-Reference-Cited by-同舟云学术

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Published:2010-01 Issue:9712 Volume:375 Page:396-407
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Eron Joseph J,Young Benjamin,Cooper David A,Youle Michael,DeJesus Edwin,Andrade-Villanueva Jaime,Workman Cassy,Zajdenverg Roberto,Fätkenheuer Gerd,Berger Daniel S,Kumar Princy N,Rodgers Anthony J,Shaughnessy Melissa A,Walker Monica L,Barnard Richard JO,Miller Michael D,DiNubile Mark J,Nguyen Bach-Yen,Leavitt Randi,Xu Xia,Sklar Peter

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. The cost effectiveness of combination antiretroviral therapy for HIV disease;Freedberg;N Engl J Med,2001

2. The survival benefits of AIDS treatment in the United States;Walensky;J Infect Dis,2006

3. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi;Jahn;Lancet,2008

4. Antiretroviral treatment for adult HIV infection: 2008 recommendations of the International AIDS Society—USA panel;Hammer;JAMA,2008

5. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection;Walmsley;N Engl J Med,2002

Cited by 276 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world prevalence of integrase inhibitor resistance and virological failure since adoption as guideline-preferred therapy;Drugs in Context;2024-05-16

2. Incidence of Hyperlipidemia among Adults Initiating Antiretroviral Therapy in the HIV Outpatient Study (HOPS), USA, 2007–2021;AIDS Research and Treatment;2023-11-30

3. Switch to a raltegravir‐based antiretroviral regimen in people with HIV and non‐alcoholic fatty liver disease: A randomized controlled trial;HIV Medicine;2023-08-28

4. Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144;Viruses;2023-06-11

5. Association between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: a systematic review and meta-analysis;BMJ Open Diabetes Research & Care;2023-02